Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C128H194N40O28S2 |
Molecular Weight | 2805.291 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 22 / 22 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CS[C@@H]2CC(=O)N(CCCCCCN3C(=O)C[C@H](SC[C@H](NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@H](CC7=CC=CC=C7)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C3=O)C2=O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)CNC(=O)[C@@H]9C[C@@H](O)CN9C(=O)[C@@H]%10CCCN%10C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=JKUYFMHGTOPVMR-WQVVEKGHSA-N
InChI=1S/C128H194N40O28S2/c1-71(2)55-85(105(177)155-83(121(193)194)41-25-49-147-127(139)140)157-109(181)89(59-75-33-15-9-16-34-75)159-111(183)91(161-107(179)87(57-73-29-11-7-12-30-73)151-99(171)65-149-113(185)95-61-77(169)67-167(95)117(189)93-43-27-53-163(93)115(187)81(39-23-47-145-125(135)136)153-103(175)79(129)37-21-45-143-123(131)132)69-197-97-63-101(173)165(119(97)191)51-19-5-6-20-52-166-102(174)64-98(120(166)192)198-70-92(112(184)160-90(60-76-35-17-10-18-36-76)110(182)158-86(56-72(3)4)106(178)156-84(122(195)196)42-26-50-148-128(141)142)162-108(180)88(58-74-31-13-8-14-32-74)152-100(172)66-150-114(186)96-62-78(170)68-168(96)118(190)94-44-28-54-164(94)116(188)82(40-24-48-146-126(137)138)154-104(176)80(130)38-22-46-144-124(133)134/h7-18,29-36,71-72,77-98,169-170H,5-6,19-28,37-70,129-130H2,1-4H3,(H,149,185)(H,150,186)(H,151,171)(H,152,172)(H,153,175)(H,154,176)(H,155,177)(H,156,178)(H,157,181)(H,158,182)(H,159,183)(H,160,184)(H,161,179)(H,162,180)(H,193,194)(H,195,196)(H4,131,132,143)(H4,133,134,144)(H4,135,136,145)(H4,137,138,146)(H4,139,140,147)(H4,141,142,148)/t77-,78-,79-,80-,81+,82+,83+,84+,85+,86+,87+,88+,89-,90-,91+,92+,93+,94+,95+,96+,97-,98+/m1/s1
Molecular Formula | C128H194N40O28S2 |
Molecular Weight | 2805.291 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 22 / 22 |
E/Z Centers | 7 |
Optical Activity | UNSPECIFIED |
Deltibant is the bradykinin receptor antagonist. It was found to be a potent and selective inhibitor of the depressor response to bradykinin in the anaesthetized rat and rabbit. Deltibant affords significant protection against traumatic shock where bradykinin plays an important role in tissue injury. Such protection may be achieved through inhibition of neutrophil-endothelial interaction and protection of vascular endothelial function. Deltibant may have some effect on survival in patients with systemic inflammatory response syndrome and gram-negative sepsis. Kinin-kallikrein system could be involved in cerebral edema - treatment with deltibant appeared to alter the natural history of traumatic brain contusions by preventing the 2 degrees brain swelling. In addition, deltibant obviated the need for surgery in the majority of treated patients. Deltibant could act on the cerebral vasculature to limit dys-autoregulation and brain swelling or on the blood brain barrier to reduce cerebral edema. Deltibant has been in phase II clinical trials for the treatment of pain, immune-inflammatory diseases and stroke. However, this research has been discontinued.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9020273
Three-day continuous infusion 1 of 3 doses (0.3, 1.0, or 3.0 ug/kg/min)
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:26:47 GMT 2023
by
admin
on
Sat Dec 16 01:26:47 GMT 2023
|
Record UNII |
6151J4V7VX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7484
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | |||
|
140661-97-8
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | |||
|
70697628
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | |||
|
C071326
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | |||
|
SUB06960MIG
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | |||
|
6151J4V7VX
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | |||
|
C166885
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103953
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | |||
|
207511-94-2
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
100000083689
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | |||
|
m1037
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
HH-11
Created by
admin on Sat Dec 16 01:26:47 GMT 2023 , Edited by admin on Sat Dec 16 01:26:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|